A novel chalcone derivative suppresses melanoma cell growth through targeting Fyn/Stat3 pathway

A novel chalcone derivative has antitumor activity in melanoma by inducing DNA damage through the upregulation of ROS products

(2020) Keke Li et al.   Cancer Cell International

3PO as a Selective Inhibitor of 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 in A375 Human Melanoma Cells

(2020) KRZYSZTOF KOTOWSKI et al.   ANTICANCER RESEARCH

The phosphorylation of CD147 by Fyn plays a critical role for melanoma cells growth and metastasis

(2020) Xu Zhang et al.   ONCOGENE

Aberrant expression of miR-125a-3p promotes fibroblast activation via Fyn/STAT3 pathway during silica-induced pulmonary fibrosis

(2019) Qi Xu et al.   TOXICOLOGY

STAT3: A Promising Therapeutic Target in Multiple Myeloma

(2019) Chong et al.   Cancers

Targeted therapy for malignant melanoma

(2019) Henrik F Lorentzen   CURRENT OPINION IN PHARMACOLOGY

The Multifaceted p21 (Cip1/Waf1/CDKN1A) in Cell Differentiation, Migration and Cancer Therapy

(2019) Kreis et al.   Cancers

STAT3 and STAT5 Activation in Solid Cancers

(2019) Sebastian Igelmann et al.   Cancers

CX-F9, a novel RSK2 inhibitor, suppresses cutaneous melanoma cells proliferation and metastasis through regulating autophagy

(2019) Xu Zhang et al.   BIOCHEMICAL PHARMACOLOGY

STAT3 and apoptosis challenges in cancer

(2018) Nazanin Fathi et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib

(2018) Liwei Lang et al.   Journal of Hematology & Oncology

Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

(2018) Michele Maio et al.   LANCET ONCOLOGY

TRAF6 regulates EGF-induced cell transformation and cSCC malignant phenotype through CD147/EGFR

(2018) Xu Zhang et al.   Oncogenesis

EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer

(2018) Laura E. Pascal et al.   NEOPLASIA

Vitexin compound 1, a novel extraction from a Chinese herb, suppresses melanoma cell growth through DNA damage by increasing ROS levels

(2018) Nian Liu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Sex differences in the association of cutaneous melanoma incidence rates and geographic ultraviolet light exposure

(2017) Feng Liu-Smith et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

AZD0530 sensitizes drug-resistant ALK-positive lung cancer cells by inhibiting SRC signaling

(2017) Yi Zhao et al.   FEBS Open Bio

Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology

(2016) Raghuveera Kumar Goel et al.   CANCER AND METASTASIS REVIEWS

Fyn deficiency attenuates renal fibrosis by inhibition of phospho-STAT3

(2016) Hye-Young Seo et al.   KIDNEY INTERNATIONAL

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

(2016) Paolo A Ascierto et al.   LANCET ONCOLOGY

Immune-checkpoint blockade — durable cancer control

(2016) Elizabeth I. Buchbinder et al.   Nature Reviews Clinical Oncology

PD-1, CTLA-4 Point to Drug Response

(2016)   Cancer Discovery

Epigallocatechin-3-gallate(EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity

(2016) Jianglin Zhang et al.   Oncotarget

Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor–Refractory Metastatic Melanoma

(2016) Guo Chen et al.   JAMA Oncology

Fyn-phosphorylated PIKE-A binds and inhibits AMPK signaling, blocking its tumor suppressive activity

(2015) S Zhang et al.   CELL DEATH AND DIFFERENTIATION

Constitutive activation of STAT3 in breast cancer cells: A review

(2015) Kasturi Banerjee et al.   INTERNATIONAL JOURNAL OF CANCER

Src family kinases differentially influence glioma growth and motility

(2015) Laura J. Lewis-Tuffin et al.   Molecular Oncology

Fyn is an important molecule in cancer pathogenesis and drug resistance

(2015) Daniel Elias et al.   PHARMACOLOGICAL RESEARCH

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial

(2014) A. Adenis et al.   ANNALS OF ONCOLOGY

Expression analysis of genes and pathways associated with liver metastases of the uveal melanoma

(2014) Yuanyuan Zhang et al.   BMC Medical Genetics

Non-invasive remote limb ischemic postconditioning protects rats against focal cerebral ischemia by upregulating STAT3 and reducing apoptosis

(2014) ZHIGANG CHENG et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Targeting Fyn in Ras-transformed cells induces F-actin to promote adherens junction-mediated cell-cell adhesion

(2014) Sarah E. Fenton et al.   MOLECULAR CARCINOGENESIS

Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma

(2014) Tobias Bald et al.   NATURE

Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell linesin vitro

(2013) Richard S. Finn et al.   HEPATOLOGY

Targeting Oncogenic Drivers and the Immune System in Melanoma

(2012) Grant A. McArthur et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib

(2011) Li Wang et al.   CLINICAL SCIENCE

Fyn

(2010) Yoshihito D. Saito et al.   CANCER